Regulation & Compliance

Edgewise Therapeutics unveils strong Phase 2 data for its HCM drug, EDG-7500, showing efficacy without the cardiac risks plaguing market leaders.

With a $240M user savings claim and top liquidity, MEXC's zero-fee model is a bold market play. But is it sustainable, and can its security promises hold up?

Enterprises have poured billions into data and AI, but many still struggle to turn insights into action. A new suite of tools aims to fix the disconnect.

Onix launches its Wingspan platform in Europe, introducing proprietary 'Semantic Twin' technology to help regulated industries navigate the EU's strict AI compliance maze.

As AI evolves from generating text to taking autonomous action, its true value hinges on a single factor: trust. Here’s why that makes data the real hero.

With a historic $1.1B in funding, David Silver's Ineffable Intelligence partners with Google Cloud to build an AI that learns from experience, not just data.

Arman Tsarukyan's $1M wager turned into a massive payout, but the viral win for betting platform Jack.com raises serious questions about sports integrity.

In an age of AI traders and instant data, one expert argues that the most valuable asset remains timeless: human discipline. But is this enough to navigate our volatile future?

Great Estate Blockchain divests its main revenue source after a flawed deal structure implodes, leaving the penny-stock firm seeking a new identity.

BlackRock Canada is shifting five iShares ETFs to new indices, updating the core methodology to include intangibles and buybacks, a move expected to create capital gains.

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

Exodus Movement's May metrics reveal a complex picture: rising transaction volumes and strategic asset shifts signal deep engagement, but a flat user count raises questions.

The financial giant sets its 2027 Investor Day. Beyond the date, it's a signal of intent for navigating a fractured world with a $4.9T balance sheet.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

CrowdStrike's new Continuous Identity platform isn't just a product; it's a foundational shift for securing the coming wave of autonomous AI agents.

A new report reveals less than half of Ontario's long-term care homes got proactive inspections, exposing a deep disconnect between policy and resident safety.

A Texas-based, private equity-backed firm just acquired a beloved local dermatology practice. It’s a story of national expansion, but what does it mean for care?

A small town lost a legal fight with a mega-church over a temple's height. Now, its public appeal is testing the limits of a powerful federal law.